Last reviewed 2026-05-14 · How we verify

Artil (ISOXEPAC)

Phase 2 active Small molecule

Artil (generic name: ISOXEPAC) is a isoxepac drug. It is currently in Phase 2 development.

Artil works by interacting with a specific molecular target to produce a therapeutic effect.

Artil (ISOXEPAC) is a small molecule isoxepac drug with unknown target and commercial status. Its mechanism of action is not publicly disclosed, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetics, safety, and efficacy. Further research is needed to understand its potential therapeutic applications and risks. Due to the lack of publicly available data, Artil's status as a patented or generic drug, and its approved indications, if any, remain unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ISOXEPAC
Drug class	isoxepac
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Artil is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how Artil works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Artil CI brief — competitive landscape report
Artil updates RSS · CI watch RSS

Frequently asked questions about Artil

What is Artil?

Artil (ISOXEPAC) is a isoxepac drug.

How does Artil work?

Artil works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Artil?

ISOXEPAC is the generic (nonproprietary) name of Artil.

What drug class is Artil in?

Artil belongs to the isoxepac class. See all isoxepac drugs at /class/isoxepac.

What development phase is Artil in?

Artil is in Phase 2.

Drug class: All isoxepac drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing